EBOS Group Limited (EBOS) notes the announcement by the Australian Competition and Consumer Commission (ACCC) today that it will not oppose the proposed acquisition of LifeHealthcare announced on 9 December 2021.
The transaction remains subject to satisfaction of certain conditions precedent and the parties continue to work diligently towards completion of the transaction, which is expected in FY22.
The ACCC will not oppose the proposed acquisition of Australian Pacific Health Supplies TopCo1 Pty Limited and its subsidiaries (Pacific Health Group) by EBOS Group Limited (ASX: EBO), through its subsidiary EBOS Medical Devices Australia Pty Limited.
EBOS and Pacific Health Group distribute a range of medical devices to private and public hospitals and to clinicians. Pacific Healt h Group also manufactures and distributes allografts through its Australian Biotechnologies business. In general, the majority of the parties’ offerings are complementary and not in direct competition.
A copy of the statement by the ACCC is attached.
Comments from our readers
No comments yet
Add your comment:
Related News:
September 3rd Morning Report
Devon Funds Morning Note - 2 September 2025
Devon Funds Morning Note - 1 September 2025
September 1st Morning Report
POT Financial Results for the year to 30 June 2025
MOVE FY25 Results for the year ended 30 June 2025
BPG - Completion of Retail Offer
Comvita releases results for the year ended 30 June 2025
August 29th Morning Report
Air New Zealand announces 2025 financial result